secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rani Therapeutics Holdings, Inc. (RANI)
CIK:        0001856725
Form:       8-K
Filed at:   2023-12-19T23:59:59+00:00
Accession:  0000950170-23-071478
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Rani Therapeutics reprices stock options for executives to $2.84 per share
--------------------------------------------------------------------------

- Board approved reducing exercise price of certain outstanding options to $2.84 per share (closing price on Dec 16, 2023).
- CEO Talat Imran: 936,444 options repriced from $5.44-$19.56; CFO Svai Sanford: 313,558 options from $5.44-$13.21.
- CSO Mir Hashim: 328,374 options repriced from $5.44-$13.21; all options retain original vesting schedules and expiration dates.
- Repricing covers employees, named executive officers, consultants, and non-employee directors; no other terms modified.
- Board determined repricing best for retention and incentivization without cash outlay or additional equity dilution.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1856725/000095017023071478/0000950170-23-071478-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1856725/000095017023071478/rani-20231216.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-071478

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer